C3N-02923
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
- age_years
- 59.94798084
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.640
- TNFA_SIGNALING_VIA_NFKB+0.620
- IL6_JAK_STAT3_SIGNALING+0.600
- ALLOGRAFT_REJECTION+0.560
- INFLAMMATORY_RESPONSE+0.560
- COMPLEMENT+0.510
- INTERFERON_GAMMA_RESPONSE+0.510
- TGF_BETA_SIGNALING+0.490
- ANGIOGENESIS+0.480
- COAGULATION+0.460
Top 10 suppressed
- MYC_TARGETS_V2-0.640
- MYC_TARGETS_V1-0.540
- E2F_TARGETS-0.520
- OXIDATIVE_PHOSPHORYLATION-0.470
- CHOLESTEROL_HOMEOSTASIS-0.400
- G2M_CHECKPOINT-0.400
- GLYCOLYSIS-0.330
- MTORC1_SIGNALING-0.330
- DNA_REPAIR-0.320
- UNFOLDED_PROTEIN_RESPONSE-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 2cec663c-00c8-48b5-967b-f2a53c0fb409 | — | — | 0.952 |
| 2 | TCGA-78-8648-01A-11R-2403-07 | — | cohortMD2 | 0.949 |
| 3 | c277dab0-361f-4aa6-96b1-522a6e556ae1 | — | — | 0.944 |
| 4 | TCGA-AN-A0FN-01A-11R-A034-07 | — | A | 0.943 |
| 5 | TCGA-CR-7376-01A-11R-2132-07 | — | — | 0.939 |
| 6 | TCGA-77-A5FZ-01A-31R-A27Q-07 | — | cohortMD2 | 0.938 |
| 7 | cf9ea065-c101-48e2-a1ea-54eb01658eef | — | — | 0.938 |
| 8 | b02dc7a2-3615-4b6c-a3dd-a866d8561d9d | — | — | 0.935 |
| 9 | TCGA-55-8299-01A-11R-2287-07 | — | cohortMD2 | 0.934 |
| 10 | SRR8613803 | — | D | 0.934 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.640 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.620 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.600 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.560 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.560 | Idelalisib | — uncovered |
| COMPLEMENT | 0.510 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.510 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.490 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.480 | Remibrutinib | — uncovered |
| COAGULATION | 0.460 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.440 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.430 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.410 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.370 | Idelalisib | — uncovered |
| APOPTOSIS | 0.360 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.340 | Inavolisib | — uncovered |
| MYOGENESIS | 0.330 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.320 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.270 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.110 | Inavolisib | — uncovered |